Navigation Links
TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
Date:9/22/2009

d vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

'/>"/>
SOURCE  Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related medicine news :

1. Boston Scientific PROMUS(R) and First-Generation TAXUS(R) Express(R) Stents Continue Excellent Performance in SPIRIT III Trial
2. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
3. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
4. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
5. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
6. TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
7. A consistent decline in heart attack rates following the implementation of smoking bans
8. Drug-eluting stents safe, effective for treatment of chronic total occlusions
9. Researchers find drug-eluting stents safe, effective for PCI in diabetics
10. New type of sirolimus-eluting stent demonstrates superior results
11. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Our Lady of Lourdes Health Care Services Inc., ... agreed to pay the United States $7.95 million to ... Department announced today. The two hospitals are Our Lady ... Lourdes Medical Center of Burlington County (LMC) in Willingboro, ... suit brought by a whistleblower, Tony Kite, in 2005. ...
(Date:12/15/2009)... If swine flu were worse, ,we would have really ... (HealthDay News) -- The outbreak of the pandemic H1N1 ... ability to respond to public health emergencies, a new ... for America,s Health and the Robert Wood Johnson Foundation, ... underfunded public health system. , "The 2009 H1N1 outbreak ...
(Date:12/15/2009)... to be leaders in the fight against malaria ... experts in online learning, the Masie Center and ... -- ONE and Malaria No More ... first-ever "Malaria Griots" program, a dynamic education course ... leaders in the fight against malaria. ,, ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., ... that, "it doesn,t matter whether there,s a public option. ... public option - give government authority over how your ... new social agenda by shifting billions of dollars from ... immigrants, and local politicians." ,, Betsy McCaughey ...
(Date:12/15/2009)... Strike Force Operations Lead to Indictment of 30 ... more than $61 Million in Fraudulent Billing to ... -- Thirty people have been charged in three ... submit more than $61 million in false Medicare ... the Medicare Fraud Strike Force, Department of Health ...
Breaking Medicine News(10 mins):Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 2Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 5
... Inc. at its,Ithaca, NY operation recently announced it ... prolonged post-operative pain relief,lasting at least five days ... Lynch. This technology addresses the need identified by,Dr. ... a long acting,local anesthetic without the common side ...
... has been,appointed executive vice president and chief operating ... of health benefits., Rhodes previously served as ... BlueShield of South Carolina in Columbia, S.C., an,independent ... Association. He,brings to TCC a background in strategic ...
... A leading authority on neurological disorders of consciousness, ... Center in New York City has received a ... the Society for Neuroscience, the world,s largest organization ... and nervous system. , The award -- for ...
... Fla., Dec. 13 The Quantum Group,Inc. (Amex: ... it,has completed its registered public offering, raising $13.2 ... it has initiated trading,on the American Stock Exchange ... the symbol "QGP.U." In addition, Quantum common shares,formerly ...
... American Stock Exchange(R),(Amex(R)) today lists the common stock and ... QGP and QGP.U. One unit consists of three shares ... Class "B" Warrants,(QGP.WS.B). The common stock and units will ... listed at a later date upon separation of the,unit., ...
... in males and females in order to alleviate back ... to research spearheaded at The University of Texas at ... first time in the Dec. 13 issue of Nature. ... least two million years ago, in the early human ...
Other Medicine News:Health News:Capsulated Systems, Inc. Develops Long Term Local Anesthetic 2Health News:Dr. Nicholas Schiff receives research award for Innovation in Neuroscience 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:American Stock Exchange Lists the Common Stock and Units of The Quantum Group, Inc. 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2
(Date:12/15/2009)... BALTIMORE, Dec. 15 Champions Biotechnology, ... engaged in the development of advanced preclinical platforms ... of oncology drugs, today announced its financial results ... 2009. Full details of Company,s financial results ... www.championsbiotechnology.com . ,, Total revenues for the ...
(Date:12/15/2009)... -- The U.S. Food and Drug Administration (FDA) Endocrinologic ... yes, 4 no, and 1 abstention that AstraZeneca has ... support the use of CRESTOR® (rosuvastatin calcium) in individuals ... or equal to 50 years, women greater than or ... 130 mg/dL; hsCRP greater than or equal to 2.0 ...
(Date:12/15/2009)... 15 Dakim, Inc. and Alzheimer,s Weekly today ... Ones, Brain Health Contest, designed to help five seniors ... and Alzheimer,s disease. All five winners will receive a ... to help seniors preserve their brain health and the ... living communities across the country. ,, The ...
Breaking Medicine Technology:Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 55 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Yerkes researchers propose ambitious new strategies for AIDS vaccine research 53971 1Yerkes researchers propose ambitious new strategies for AIDS vaccine research 53971 2Yerkes researchers propose ambitious new strategies for AIDS vaccine research 53971 3The hepatitis healing power of blueberry leaves 9519 1GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 1GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 2GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 3GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 4GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 5GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 6GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 7
... Up to 24 Hours After,Exposure to Anthrax, ... Targanta,Therapeutics Corporation announced today the results from ... therapy for treating,exposure to Bacillus anthracis, the ... Oritavancin, a novel semi- synthetic,lipoglycopeptide antibiotic for ...
... GTx, Inc., (NASDAQ:,GTXI) announced today that data from ... of Ostarine(TM) and from the ongoing Phase,III clinical ... treatment of multiple side effects of androgen,deprivation therapy ... Meeting of the American Society of Clinical Oncology ...
Other Medicine Technology:Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 2Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 3Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 4GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
...
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
Medicine Products: